The 7 largest psychedelic drug stocks, as tracked in our munKNEE Psychedelic Drug Stocks index, are ranked below, in descending order, as to their performances in the month of May and YTD.

1. Seelos (SEEL): UP 34.8% in May; UP 43.1% YTD
   • is primarily focused on the use of ketamine*. Go here for much more extensive information on Ketamine.
   • Read: Seelos Addressing Significant And Unmet Needs In Rare Psychiatric And Movement Disorders
2. GH Research (GHRS): UP 32.1% in May; UP 16.4% YTD
   • is primarily focused on the use of mebufotenin*, the new International non-proprietary name for 5-MeO-DMT, which stands for 5-MethOxy-N,N-DiMeThyltryptamine but is better known by its nickname, “The Toad”,
   • Read: GH Resources: Focus On Treatment-Resistant Depression Paying Off 
3. Atai (ATAI): DOWN 6.3% in May; DOWN 30.6% YTD
   • is primarily focused on the use of ketamine*, DMT* and ibogaine*.  Go here for much more extensive information on Ketamine and here for much more extensive information on DMT.
   • Read: Atai Life Sciences: Long On Money; Short On Success
4. Mind Medicine (MNMD): DOWN 7.3% in May; UP 62.4% YTD
   • is primarily focused on the use of LSD* and MNMA*. Go here for much more extensive information on LSD and  here for much more extensive information on MNMA.
   • Read: MindMed: Researching LSD And MNMA To Treat Neurological Diseases
5. Compass Pathways (CMPS): DOWN 8.5% in May; DOWN 6.0% YTD
   • is primarily focused on the use of psilocybin* (magic mushrooms) in their research. Go here for much more extensive information on Psilocybin.
6. Incannex Healthcare (IXHL): DOWN 13.0% in May; DOWN 27.7% YTD
   • engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies and has the largest portfolio of such products an therapies worldwide with a potential global addressable market for all Incannex' products under development exceeds $400B per annum.
   • Read: Incannex Healthcare Has World's Largest Pipeline Of Psychedelic Products
7. Cybin (CYBN): DOWN 22.9% in May; DOWN 6.9% YTD
   • is primarily focused on the use of DMT* and Psilocybin*. Go here for much more extensive information on DMT and here for much more extensive information on Psilocybin.

*Read 10 Psychedelic Substances And The 36 Companies Researching Them for a description of each of the psychedelic-based compounds mentioned in this article.

Summary:

The munKNEE Psychedelic Drug Stocks Index was UP 5.9% in May and is now UP 3.9% YTD.

If you are interested in this category of clinical-stage psychedelic compound-based stocks consider the  AdvisorShares Psychedelic ETF (PSIL) which consists of 23 such stocks but keep in mind that the vast majority have market capitalizations of $50M or less (i.e. are nano-caps). It was DOWN 1.7% in May and is now DOWN 22.7% YTD.

More By This Author:

Largest Canadian Cannabis LP Stocks Down 22% In May
Largest Plant-Based Food Stocks Down 29.5% In May
Largest Canadian Cannabis Companies Collapsed 16%, On Average, This Week